Inovio Pharmaceuticals, Inc. (INO)

NCM – Real Time Price. Currency in USD

0.84

+0.04 (5.48%)

At close: Oct 22, 2026, 4:00 PM EDT

0.85

+0.01 (1.32%)

After-hours: Oct 22, 2026, 7:40 PM EDT

20.10.2026

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI, Inc. ("VGXI") and GeneOne Life Science, Inc. ("GeneOne") in the case captioned INOVIO Pharmaceuticals, Inc. v.

14.09.2026

Bet on 4 Top-Ranked Stocks With Rising P/E

Tap four stocks with increasing P/E ratios to try out an out-of-the-box investment approach.

11.09.2026

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

11.09.2026

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals NASDAQ: INO said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.

10.09.2026

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.

09.09.2026

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

03.09.2026

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap these five stocks - CURI, INO, GDS, NMG and CCOI - with increasing P/E ratios to try out an out-of-the-box approach.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
INO	Jefferies	Buy	undefined >> $3	August 13th 2026

Press releases

20.10.2026

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

12.08.2026

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial preparations advancing in anticipation of potential product launch for INO-3107 Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences Current cash, cash equivalents, and short-term investments anticipated to fund operations into late first quarter 2027, through a potential launch of INO-3107, if approved PLYMOUTH MEETING, Pa., Aug. 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent company developments.

Inovio Pharmaceuticals, Inc. (INO)

Get all premium features to the best stock analysis tool

Finranks

Contact us

Follow us

Inovio Pharmaceuticals, Inc. (INO)

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

Bet on 4 Top-Ranked Stocks With Rising P/E

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Bet on 5 Top-Ranked Stocks With Rising P/E

Videos

No Data

Upgrades / Downgrades

Press releases

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

Bet on 4 Top-Ranked Stocks With Rising P/E

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Bet on 5 Top-Ranked Stocks With Rising P/E

Videos

No Data

Upgrades / Downgrades

Press releases

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Search stocks

Inovio Pharmaceuticals, Inc. (INO)

Get all premium features to the best stock analysis tool

Finranks

Contact us

Follow us

Inovio Pharmaceuticals, Inc. (INO)

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

Bet on 4 Top-Ranked Stocks With Rising P/E

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Bet on 5 Top-Ranked Stocks With Rising P/E

Videos

No Data

Upgrades / Downgrades

Press releases

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

Bet on 4 Top-Ranked Stocks With Rising P/E

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Bet on 5 Top-Ranked Stocks With Rising P/E

Videos

No Data

Upgrades / Downgrades

Press releases

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights